CN Patent

CN1354622A — 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法

Assigned to United Therapeutics Corp · Expires 2002-06-19 · 24y expired

What this patent protects

本发明涉及治疗外周血管疾病和肺动脉高压的前列腺素及其类似物,其包括连接于至少一个位点的药学可接受且能够减缓向温血动物给药时活性基团代谢速率的保护基。事实上,图1图示了一个剂量的mPEG20kDa－酰胺－化合物X经静脉内输注给用肺动脉高压剂静脉内诱导的绵羊对其肺动脉压的影响。

USPTO Abstract

本发明涉及治疗外周血管疾病和肺动脉高压的前列腺素及其类似物,其包括连接于至少一个位点的药学可接受且能够减缓向温血动物给药时活性基团代谢速率的保护基。事实上,图1图示了一个剂量的mPEG20kDa－酰胺－化合物X经静脉内输注给用肺动脉高压剂静脉内诱导的绵羊对其肺动脉压的影响。

Drugs covered by this patent

treprostinil-diolamine (TREPROSTINIL DIOLAMINE)

Patent Metadata

Patent number: CN1354622A
Jurisdiction: CN
Classification: —
Expires: 2002-06-19
Drug substance claim: No
Drug product claim: No
Assignee: United Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.